Applied Evidence

Juvenile idiopathic arthritis: Old disease, new tactics

Author and Disclosure Information

 

References

Before beginning therapy with a biologic agent, it’s important to screen for hepatitis B, hepatitis C, human immunodeficiency virus infection, tuberculosis, and fungal infection (eg, Histoplasma capsulatum, Coccidioides immitis32). Be sure to make a timely referral to the ophthalmology service for a bi-annual eye exam and, in the event that surgery is necessary, conduct a preoperative evaluation, with the knowledge of how long before surgery a biologic agent must be withheld (duration varies by drug).32

CORRESPONDENCE
Tobe Momah, MD, Department of Family Medicine, Clinical Science Building, 4th Floor, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216; tmomah@umc.edu.

Pages

Recommended Reading

Take action to mitigate CVD risk in RA patients
MDedge Family Medicine
TNFi use may not affect joint replacement rates for RA patients
MDedge Family Medicine
Mediterranean diet cut Parkinson’s risk
MDedge Family Medicine
Ehlers-Danlos syndrome: Increased IUGR risk reported
MDedge Family Medicine
List of medications linked to drug-induced lupus expands
MDedge Family Medicine
AAD, NPF release two joint guidelines on treatment, management of psoriasis
MDedge Family Medicine
Death data spur black-box warning for gout drug Uloric
MDedge Family Medicine
Much still unknown about inflammation’s role in RA patients’ CVD risk
MDedge Family Medicine
FDA approves liquid colchicine for gout
MDedge Family Medicine
Is intra-articular platelet-rich plasma injection an effective treatment for knee OA?
MDedge Family Medicine